All In Biotech

Drug Trial Radar · NCT05798117

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

An Open-label, Multi-center, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Participants With Severe, Refractory Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

21

Actual

Start

Feb 28, 2023

Primary completion

Sep 24, 2026

Study completion Sep 24, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.

Conditions

  • Systemic Lupus Erythematosus
  • Lupus Nephritis

Interventions

  • YTB323Drug

    Single infusion of YTB323

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with AEs and SAEsTime frame: Day 1 to 2 years

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Bern, Switzerland

  • Novartis Investigative Site

    Lausanne, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.